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ABSTRACT:
The serine threonine kinase Akt1 has been implicated in the control of cellular 
metabolism, survival and growth. Herein, disruption of the ubiquitously expressed 
member of the Akt family of genes, Akt1, in the mouse, demonstrates a requirement 
for Akt1 in miRNA-mediated cellular apoptosis. The miR-17/20 cluster is known to 
inhibit breast cancer cellular proliferation through G1/S cell cycle arrest via binding 
to the cyclin D1 3’UTR. Here we show that miR-17/20 overexpression sensitizes 
cells to apoptosis induced by either Doxorubicin or UV irradiation in MCF-7 cells via 
Akt1. miR-17/20 mediates apoptosis via increased p53 expression which promotes 
Akt degradation. Akt1-/- mammary epithelial cells which express Akt2 and Akt3 
demonstrated increased apoptosis to DNA damaging agents. Akt1 deficiency abolished 
the miR-17/20-mediated apoptosis. These results demonstrated a novel pathway 
through which miR17/20 regulate p53 and Akt controlling breast cancer cell apoptosis.
INTRODUCTION
The cell survival oncoprotein Akt1, also known as 
protein kinase B (PKB), is frequently hyperactivated in 
human cancers. Akt1 is recruited to the plasma membrane 
in the presence of phosphoinositide triphosphate (PI-
3,4,5-P). Akt1 plays a central role in the ability of external 
signals to promote cell survival by preventing cytochrome 
c release from mitochondria (1-3) and maintaining 
mitochondrial membrane integrity by increasing 
hexokinase (HK) association with mitochondria (4). 
In mammalian cells, activating growth factors and 
oncogenes stimulate Akt1 kinase activity to promote anti-
apoptotic signaling (4). Three separate genes with high 
sequence identity encode the major isoforms of Akt1/
PKB (Akt1/PKBα, Akt2/PKBβ, Akt3/PKBγ). Substrate 
specificity of the Akt1 isoforms is similar, although Akt1 
is the predominant isoform expressed in most tissues. 
Constitutive activation of Akt1 kinase occurs in human 
cancer through deletion and mutation of the tumor 
suppressor gene PTEN, the phosphatase that negatively 
regulates Akt1, through amplification of the Akt1 genes, 
or through amplification of the catalytic subunit of PI3 
kinase (5-7). The pro-proliferative and prosurvival effects 
induced by Akt1 kinase are conducted through regulation 
of caspase 9, I B kinase , Bad, and induction of the GSK3/
cyclin D1 signaling pathways (reviewed in: (8, 9)).
ErbB2/ErbB3 receptor activation, which occurs 
frequently in breast cancer, induces PI3K and Akt1 kinase 
activity (10, 11). The ErbB2 oncogene is amplified in up 
to 30% of human breast cancers and is associated with 
poor patient prognosis in response to chemotherapeutic 
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agents. ErbB2 induces Akt1 activity, cellular growth 
and therapeutic resistance (12). The activation of ErbB2 
is an early event in human breast cancer with ErbB2 
overexpressed in up to 80% of primary ductal carcinoma 
in situ lesions (13). MicroRNAs (miRNAs) are 21-
22 nucleotide molecules that regulate the stability or 
translational efficiency of targeted messenger RNAs. 
Derived from nuclear precursor RNAs, initial processing 
occurs by the inter-nuclease Drosha to release pre-
miRNA of 60-70 nucleotides in length from pri-miRNA. 
Subsequent transport to the cytoplasm by exportin-5 
results in processing by the inter-nuclease Dicer to 
generate the ~22 nucleotide mature miRNA (14-16).The 
base pairing interactions between miRNAs and their target 
mRNAs, often within the 3’ untranslated region (3’UTR) 
of target genes, results in the degradation of target mRNAs 
(17, 18) or inhibition of their translation (19). To date more 
than 2,000 miRNAs have been identified or predicted 
in humans (miRBase Sequence Database Version 20.0 
released in Jun. 2013). It has been proposed that as each 
vertebrate miRNA may bind to as many as 200 gene 
targets, miRNAs potentially control the expression of 
about one-third of human mRNAs (20).
Several independent lines of evidence support a role 
for miRNAs in human cancer (21-25). miRNA encoding 
genes are frequently located at fragile sites, and in minimal 
regions of loss of heterozygosity, minimal regions of 
amplification, and in common breakpoint regions involved 
in cancers (26). Aberrant expression of miRNAs or 
mutations of miRNA genes have been described in many 
types of tumors. Let-7 abundance is reduced in several 
cancers including lung cancer (27), and let-7 was reported 
to regulate tumor growth by targeting the ras gene (28). 
miR-15a and miR16-1 were deleted and/or down-regulated 
in ~ 70% of patients with chronic lymphocytic leukemia 
(29). miR-15a/16-1 induced apoptosis by inhibiting BCL-
2 (30). The miR-34 family is an important component of 
the p53 tumor suppressor network (25). The human miR-
17/20 cluster’s genomic location, chromosome 13q31, 
correlates with loss of heterozygosity in a number of 
different cancers including breast cancer (31, 32). The 
expression and function of miRNA varies by cell type. 
The miR-17/20 cluster functions as a tumor suppressor 
in human breast cancer by decreasing AIB1 and cyclin 
D1 expression (33, 34). In contrast, in both lung cancer 
and lymphomas, expression of this miRNA cluster was 
increased, enhancing cell growth (22, 35). The onset and 
progression of tumorigenesis involves evasion of apoptotic 
signals, sustained cellular proliferation and the ability to 
promote tumor neoangiogenesis. As the same miRNA 
performs different functions through distinct pathways 
dependent on the tissue or cell type, it is important to 
understand the mechanisms by which miRNA regulates 
the cellular apoptosis and thereby tumorigenesis.
RESULTS
miR-17/20 sensitized stress signal-induced 
apoptosis in breast cancer cells. 
Our previous studies demonstrated the suppression 
of cellular proliferation in human breast cancer cells by 
miR-17/20. In order to determine the potential role of miR-
17/20 in regulating breast cancer cell apoptosis, MCF-7 
cells were transduced with a retrovirus encoding the miR-
17/20 cluster. The cells were treated either with 0.05 μM 
doxorubicin for 24 hours or with UV radiation and then 
analyzed for apoptosis by TUNEL assay. Apoptotic cells 
were increased in miR-17/20 overexpressing MCF-7 cells 
compared to control cells. Thus, miR-17/20 increased 
MCF-7 sensitivity to DNA damage inducing agents after 
doxorubicin or UV radiation (Fig. 1A and Supplemental 
Fig. S1). 
 In order to corroborate the effects of miR-17/20 
on apoptosis, anti-miR-17 and anti-miR-20a were applied 
to block the function of endogenous miR-17 and miR-20a. 
In MCF-7 cells, doxorubicin-induced cellular apoptosis, 
assessed by TUNEL analysis, was abolished by anti-miR 
treatment in miR-17/20 transduced MCF-7 cells (Fig. 1B).
 In order to identify the mechanisms by which 
miR-17/20 regulates cellular apoptosis, analysis was 
conducted of apoptosis-regulating pathways and target 
genes (p53, p57, Cyto C, Caspase 3, Caspase 9, Bax, 
and PARP). The expression of p53 and p27KIP1 increased 
in miR-17/20 transduced MCF-7 cells. p57 expression 
was unchanged by miR-17/20 treatment (Fig. 1C). 
Doxorubicin treatment of MCF-7 cells enhanced miR-
17/20 induction of p53 (Fig. 1D). Consistent with the 
observation, transfection of MCF-7 cells with anti-miR-17 
or anti-miR-20a decreased p53 expression (Fig. 1E). 
The effect of miR-17/20 was next assessed in the 
NAFA cell line which was derived from an ErbB2-induced 
mouse mammary tumor. miR-17/20 transduction increased 
the sensitivity of NAFA cells to doxorubicin-induced 
apoptosis as assessed by TUNEL staining (Fig. 1F). The 
induction of apoptosis in miR-17/20 transduced NAFA 
cells was associated with induction of p27, Bax, p-γ-H2A, 
caspase 9 and cleaved PARP (Fig. 1G and Supplementary 
Figure S2). Similarly,  miR-17/20 induced apoptosis in 
MCF-7 cells was associated with induction of Bax, Cyto 
C, Bcl-xs, caspase 3 and cleavage of caspase 9 and PARP 
(Fig. 2A). 
miR-17/20 increased MCF-7 cell sensitivity to 
tamoxifen. 
The anti-estrogen tamoxifen is the most commonly 
used treatment for patients with estrogen-receptor α (ER)-
positive breast cancer. Tamoxifen resistance occurs in 
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ERα+ breast cancer cells including MCF-7. miR-17/20 
transduced MCF-7 cells and control were treated with 15 
uM tamoxifen up to 36 hours. The relative cell survival 
was determined using the MTT assay. As shown in Figure 
2B, miR-17/20 overexpression attenuated relative cell 
survival in the presence of tamoxifen (Fig. 2B, C). MCF-
7 control cells showed sensitivity to 15 uM tamoxifen 
after 36h treatment while miR-17/20 transduced MCF-7 
cells showed sensitivity after 24 hours treatment when 
compared to cells without tamoxifen treatment (Fig. 2C). 
At both 24h and 35h timepoints, control MCF-7 cells 
showed more resistance to tamoxifen than miR-17/20 
transduced cells (Fig. 2C).
miR-17/20 attenuated doxorubicin resistance in 
MCF-7 cell.
MCF-7 cells were treated with different 
concentrations (0-500 nM) of doxorubicin for 48h and 
72h, followed by quantitative analysis of cell survival. 
Compared to control cells, miR-17/20 transduced MCF-
Figure 2: miR-17/20 increases tamoxifen sensitivity 
of MCF-7 cells. A, Western blot showing the regulation of 
apoptosis pathway-related genes in miR-17/20 transduced 
MCF-7 cells. B, Phase contrast images of miR-17/20 or control 
transduced MCF-7 cells after 36h treatment (15uM tamoxifen). 
Survived cells are indicated with solid arrow, apoptotic cells 
are indicated with dashed arrow. C, MTT assays measuring 
the relative survival rate of MCF-7 cells after treatment with 
tamoxifen (15uM) for the indicated times. The data are mean 
+SEM (n=5), **p<0.01.
Figure 1: miR-17/20 sensitizes doxorubicin-induced 
apoptosis, and increase p53 expression in breast cancer 
cells. A, Tunnel Assay on miR-17/20 or control transduced 
MCF-7 cells after treatment with doxorubicin at 0.05uM for 
24h. B, Tunnel Assays on anti-miR-17-, anti-miR-20a- and 
negative control-transfected MCF-7 cells after treatment with 
doxorubicin (0.05μM) for 24h. C, Western blots showing the 
increased p53 and p27KIP1 in miR-17/20 transduced MCF-7 
cells. GDI served as loading control. D, Western blots showing 
the increased p53 expression in miR-17/20 transduced MCF-7 
cells in the presence (lane 1 and 2) or absence (lane 3 and 4) 
of doxorubicin treatment. E, Western blot showing decreased 
p53 in anti-miR-17 and anti-miR-20a- transduced MCF-7 cells. 
F, miR-17/20 sensitizes NAFA cells to doxorubicin-induced 
apoptosis. G, Western blot showing increased p27KIP1 BAX, 
p-γ/H2A, PARP and Caspase 9 in miR-17/20 transduced NAFA 
cells. β-Tubulin served as loading control.
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7 showed increased sensitivity to 400 nM and 500 nM 
doxorubicin. The reduction in cell survival of miR-
17/20 transduced cells was most pronounced (~20% 
vs. ~35%) after 72h of treatment (Fig. 3A). miR-17/20 
overexpression decreased the IC50 of MCF-7 cells to 
doxorubicin (48h treatment). The MCF-7 cell growth 
curve with 500 nM doxorubicin treatment demonstrated 
significantly enhanced sensitivity to doxorubicin to 
doxorubicin after 24h of treatment (Fig. 3B). 
Akt1 is required for miR-17/20 sensitization 
of breast tumor cells to doxorubicin-induced 
apoptosis.
 Akt and p53 both are important regulators of 
stress signal-induced cellular apoptosis (36). miR-
17/20 sensitized the ErbB2-induced NAFA cell line 
to apoptosis. Akt1 is required for the progression of 
ErbB2-induced breast tumorigenesis in transgenic mice 
(37). We investigated whether Akt1 is involved in the 
miR-17/20 sensitized cellular apoptosis. We therefore 
derived breast tumor cell lines from MMTV-ErbB2/
Akt1-/- and MMTV-ErbB2/Akt1+/+ litter mate control 
mice and thereby assessed the role of Akt1 in miR-17/20 
mediated apoptosis. The mammary tumor cell lines were 
transduced with either miR-17/20 or control. Apoptosis 
assays indicated more apoptotic cells in Akt1-/- tumor cells 
than that in Akt1+/+ cells after doxorubicin treatment (Fig. 
4A). In addition to doxorubicin, puromycin was applied to 
Akt1+/+ and Akt1-/- breast tumor cells to analyze the induced 
cellular apoptosis. As shown in supplementary Figure S3, 
Akt1-/- cells were more sensitive to puromycin than Akt1+/+ 
cells at the indicated concentrations. 
 miR-17/20 transduction was able to sensitize the 
Akt1+/+ cells to doxorubicin treatment, but not Akt1-/- cells 
(Fig. 4B, C). Western analysis showed that miR-17/20 
overexpression promoted p53 expression in Akt1+/+ cells 
rather than Akt1-/-  cells (Fig. 4D). Notably, Akt1-/- cells 
Figure 4: Akt1 is required for miR-17/20 sensitization 
of breast tumor cells to doxorubicin-induced apoptosis. 
A, Annexin V staining showing the increased apoptosis in Akt1-
/- murine ErbB2 breast tumor cells treated with doxorubicin at 
0.5μM for 24h. B, Annexin V staining as a marker of apoptosis in 
miR-17/20 transduced Akt1+/+ or Akt1-/- murine ErbB2 breast 
tumor cells, **p<0.01. C, Tunnel assays for apoptosis in Akt1-/ - 
vs. Akt1+/+ murine ErbB2 breast tumor cells. D, Western blot of 
miR-17/20 transduced Akt1-/- and Akt+/+ murine ErbB2 breast 
tumor cells for p53. β-Tubulin is a loading control. E, Western 
blot of Akt1, Akt2 and Akt3 expression in Akt1-/- murine ErbB2 
mammary tumor cells. GDI served as loading control. F: Western 
blot of Akt1, total Akt, Cyto C and p53 expression in multiple 
WT and Akt1-/- murine ErbB2 mammary tumors. 
Figure 3: miR-17/20 increases the sensitivity of MCF-7 
cells to doxorubicin. A, Cell survival of miR-17/20 or control 
transduced MCF-7 cells after treatment with doxorubicin at 
indicated concentrations for 48h and 72h. B, Cell survival curves 
of miR-17/20 and control transduced MCF-7 treated with 0.5 
μM doxorubicin for 0, 24, 48, and 72 hours. The data represent 
mean + SEM (n=5).
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showed much more p53 expression than Akt1+/+ cells (Fig. 
4D), which is consistent with our observation of more 
apoptotic cells in Akt1-/- cells. Interestingly, increased Akt2 
and Akt3 expression was detected in Akt1-/- cells compared 
to Akt1+/+ cells (Fig. 4E). Additional analysis on multiple 
breast tumor samples from Akt1-/-  mice also showed 
increased expression of p53 and Cyto C compared with 
Akt1+/+ mice (Fig.4F).
DISCUSSION
The current studies demonstrated that miR-17/20 
induces apoptosis in response to the DNA damaging agents 
doxorubicin and tamoxifen. MiR-17/20 transduction of 
MCF-7 cells induced p53 and apoptosis characterized by 
induction of BAX, release of cytochrome C and induction 
of Bcl-X(S). Using Akt1 knockout mammary epithelial 
cells, and breast cancer derived cell lines from transgenic 
mice, we demonstrated the induction of p53 by miR-17/20 
required Akt1. Akt1 inhibited p53 abundance in cultured 
mammary epithelial cells. These studies identify a novel 
pathway by which the non-coding genome mediates 
apoptosis in response to DNA damaging agents, and 
thereby enhances sensitivity to drug treatment.
In the current studies, miR-17/20 enhanced 
tamoxifen-induced apoptosis. Addition of tamoxifen 
induced apoptosis with a 4-fold increase in cellular 
apoptosis at 24 hours. In prior studies, tamoxifen-induced 
apoptosis was shown to involve the estrogen receptor 
ERα and additional signaling kinases, including protein 
kinase C, calmodulin TGF-α, map kinases including JNK 
and p38 map kinase, and oxidative stress involving the 
mitochondrial permeability transition (38)(Reviewed in 
(39)). 10 uM tamoxifen treatment induces genotoxic stress 
in MCF-7 cells via a DNA damage response through free-
radical production (40).
Consistent with the role of the miR-17/20 in 
growth inhibition, the human miR-17/20 cluster, 
which is located on chromosome 13q31, undergoes 
loss of heterozygosity in a number of malignancies, 
including breast cancer. In transgenic mice, miR-17/20 
overexpression reduced overall tissue growth resulting 
in small organs (41). In breast cancer cells, the cell 
cycle is controlled through a cyclin D1-miR-17/20 auto-
regulatory feedback loop (33). Consistent with a model 
in which miRNA-17 retards cellular growth in transgenic 
mice, these studies demonstrated miR-17/20 inhibits 
cyclin D1 gene expression via a 3’ UTR binding site. The 
cyclin D1 3’ UTR is spliced in the normal population 
(41). The miR-17/20-mediated inhibition of breast 
cancer cellular proliferation via cyclin D1 repression, 
together with the finding that miR-17/20 inhibits breast 
cancer cell invasiveness (42), is consistent with a model 
in which miR-17/20 is a negative growth regulator in 
breast cancer cells. In this regard, miR-17/20 levels were 
reduced in highly invasive breast cancer cell lines and 
node-positive breast cancer specimens (42). Furthermore, 
cell conditioned media from miR-17/20 overexpressing 
MCF-7 cells inhibited the invasiveness of MDA-MB-231 
cells by inhibiting secretion of several cytokines and 
Figure 5: Schematic representation of the molecular mechanisms by which miR-17/20 and Akt1 regulate p53 abundance 
and thereby apoptosis.
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plasminogen activators. In the current work we found the 
apoptosis induction by miR-17/20 in breast cancer cells. 
miR-17/20 overexpression induced the expression of p53, 
Bax, Cyto C and caspases which are key components 
of p53-mediated apoptosis pathway (Figure 2A and 
Supplementary Figure S4). 
In terms of same “seed” sequence shared by miR-
17 and miR-20a,1,220 conserved target genes for both 
miR-17 and miR-20a are predicted by TargetScan tool, in 
which quite a few genes are involved in cellular apoptosis 
regulation including caspase 7, caspase 2, BCL2-like 
11, et al. Ingenuity Pathway Analysis (IPA) on the 1,220 
predicted target genes revealed a cell death network 
(Supplemental Figure S5) and a cellular apoptosis pathway 
(Supplemental Figure S6).
Deletion of Akt1 abrogated both the inhibition of 
cellular proliferation and the induction of apoptosis by 
miR-17/20. In the current studies, Akt1 was required for 
miR-17/20-mediated induction of p53 abundance. These 
findings are consistent with prior observations that Akt1 
stabilized p53 in response to DNA damaging agents. 
Double-stranded DNA breaks induce cellular lesions that 
may lead to chromosomal rearrangements and instability. 
Defense mechanisms to maintain stability include cell 
cycle arrest, DNA repair, and apoptosis. The double-
stranded DNA breaks induced by DNA damaging agents, 
including doxorubicin, as used in the current studies, are 
recognized by large phosphatidylinositol 3 protein kinases, 
including Ataxia Telangiectasia Mutated (ATM) and DNA-
dependent Protein Kinases (DNA-PK) which sequentially 
implement the DNA damage response. In resting cells 
the levels of p53 protein are low due to the activity of 
E3 ubiquitin ligases (MDM2, Pirh2, and COP1). Akt2 was 
required for irradiation-induced p53 stabilization (43). In 
mouse embryo fibroblasts and lymphoblasts, this DNA-
PKc/Akt/GSK3á/Mdm2 signaling pathway prevented 
Mdm2-mediated p53 degradation. In the current studies, 
the Akt1-/- MEC cells expressed both Akt2 and Akt3, 
indicating that Akt1 is necessary in mammary epithelial 
cells for this signaling pathway.
MATERIALS AND METHODS
Cell culture and reagents.
 Murine mammary epithelial tumor cells (MMTV-
ErbB2/Akt1+/+ or MMTV-ErbB2/Akt1-/-) were isolated 
from MMTV-ErbB2 mammary gland tumors generated 
in bi-transgenic mice, and maintained as previously 
described (37). The NAFA cell line derived from the 
MMTV-NeuT transgenic mouse was cultured in DMEM 
containing penicillin and streptomycin (100 mg of each/L) 
and supplemented with 10% fetal bovine serum (FBS). 
Tamoxifen (MP Bio), doxorubicin (Sigma), were used at 
doses and for the times indicated in the individual figure 
legends.
Retrovirus infection, small RNA/plasmid 
transfection. 
miR-17/20Retroviral production and infection 
methods were described in detail before (40). The 
ecotropic packaging vector, pSV- –E-MLV which 
providesecotropic packaging helper function, was used 
with retrovirus to infect cells. F For cellular transfection 
with anti-miRNA (Ambion), RNAiMax (Invitrogen) was 
used following the manufacturer’s instructions. 
Western blot analysis.
 Whole-cell lysates (50 μg) were separated by 
10% SDS-PAGE, and the proteins were transferred to 
nitrocellulose membrane. The following antibodies were 
used for Western blotting: anti-cyclin D1 from Neomarker 
(Fremont, CA); anti-Bcl-Xs from Calbiochem (Darmstadt, 
Germany); anti-β-Tubulin (sc-9104), anti-β-actin (sc-
47778), anti-p53 (sc-6243G), anti-p57 (sc-1040), anti-p27 
(sc-528), anti-Cytochrome C (SC-7159), anti-Bax (sc-
7480), anti-BCL-2 (sc-7382), anti PARP (sc-7150), 
anti-Caspase 9 (sc-8355), anti-Caspase 3 (sc-7148) were 
from Santa Cruz Biotechnology (Santa Crus, CA); anti-
GDI from RTG Solutions (Gaithersburg, MD); anti-Akt1 
(#2967 ), anti-Akt2 ( #5239 ), anti-Akt3 (#4059 ), anti-p-
y-H2A ( #9718s ) were from Cell Signaling.
Cell proliferation assays.
 MCF-7 Cells were infected with the pMSCVpuro-
miR-17/20 cluster or the pMSCVpuro empty vector. After 
puromycin selection, 4x104 cells were seeded into each 
well of a 6-well plate in triplicate and cell number was 
counted daily for 3 to 4 days under a microscope using a 
hemocytometer. For the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium(MTT) assay, 4x103 cells/well were 
seeded into a 96-well plate in triplicate and cell growth 
was measured after 24 hours’ culture. 
TUNEL assay. 
miR-17/20 transduced cells and control were 
cultured in medium containing doxorubicin (0.05μM). 
After 24-48 hours cells were plated into 96-well plate 
in triplicate. Apoptosis assays were performed using 
the In Situ Cell Death Detection Kit, TMR red (Roche 
Diagnostics, Mannheim, Germany) following the 
manufacturer’s instructions.
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Annex V staining.  
Akt1+/+ and Akt1-/ - murine ErbB2 breast tumor cells 
were incubated with fluorochrome-conjugated Annexin V 
followed by Propidium Iodide staining solution treatment. 
Flow cytometry analysis was applied to measure apoptotic 
cells. 
miRNA target gene prediction and pathway 
analysis.
The target gene prediction of hsa-miR-17 and hsa-
miR-20 was performed using TargetScan Human 6.2 
version (released June 2012) (http://www.targetscan.
org/). The predicted target genes were further analyzed 
for pathway analysis and network analysis using Ingenuity 
Pathway Analysis (IPA).
Statistical analysis. 
Data are presented as mean + SEM. The standard 
two-tailed student’s t-test was used for analysis and 
P<0.05 was considered significant.
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